308 results on '"Chen, Chiung-Tong"'
Search Results
2. Benzo[b]thiophene-2-carboxamides as novel opioid receptor agonists with potent analgesic effect and reduced constipation
3. Selective and antagonist-dependent µ-opioid receptor activation by the combination of 2-{[2-(6-chloro-3,4-dihydro-1(2H)-quinolinyl)-2-oxoethyl]sulfanyl}-5-phenyl-4,6-(1H,5H)-pyrimidinedione and naloxone/naltrexone
4. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization
5. Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease
6. A bubble bursting-mediated oral drug delivery system that enables concurrent delivery of lipophilic and hydrophilic chemotherapeutics for treating pancreatic tumors in rats
7. A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus
8. The in vivo antinociceptive and μ-opioid receptor activating effects of the combination of N-phenyl-2′,4′-dimethyl-4,5′-bi-1,3-thiazol-2-amines and naloxone
9. CCM111 prevents hepatic fibrosis via cooperative inhibition of TGF-β, Wnt and STAT3 signaling pathways
10. Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2
11. Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery
12. Enhanced B-Raf-mediated NRF2 gene transcription and HATs-mediated NRF2 protein acetylation contributes to ABCC1-mediated chemoresistance and glutathione-mediated survival in acquired topoisomerase II poison-resistant cancer cells
13. PSPC1 mediates TGF-β1 autocrine signalling and Smad2/3 target switching to promote EMT, stemness and metastasis
14. N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors
15. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations
16. Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles
17. Noninvasive imaging oral absorption of insulin delivered by nanoparticles and its stimulated glucose utilization in controlling postprandial hyperglycemia during OGTT in diabetic rats
18. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT
19. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)
20. Effects of pH on molecular mechanisms of chitosan–integrin interactions and resulting tight-junction disruptions
21. Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules
22. Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors
23. Elucidating the signaling mechanism of an epithelial tight-junction opening induced by chitosan
24. Omicron‐specific mRNA vaccine induced cross‐protective immunity against ancestral SARS‐CoV‐2 infection with low neutralizing antibodies.
25. Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)
26. Immune response and pathophysiological features of Klebsiella pneumoniae liver abscesses in an animal model
27. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins
28. BPR0C261, An Analogous of Microtubule Disrupting Agent D-24851 Enhances the Radiosensitivity of Human Non-Small Cell Lung Cancer Cells via p53-Dependent and p53-Independent Pathways.
29. Targeting the Phosphatidylserine-Immune Checkpoint with a Small-Molecule Maytansinoid Conjugate.
30. Protective Effect of CXCR4 Antagonist DBPR807 against Ischemia-Reperfusion Injury in a Rat and Porcine Model of Myocardial Infarction: Potential Adjunctive Therapy for Percutaneous Coronary Intervention.
31. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery
32. Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors
33. The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b.
34. Synthesis and Evaluation of Small Molecule Drug Conjugates Harnessing Thioester-Linked Maytansinoids.
35. Candida albicans ENO1 null mutants exhibit altered drug susceptibility, hyphal formation, and virulence
36. R432 is a key residue for the multiple functions of Ndt80p in Candida albicans
37. Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents
38. Shengmai San reduces hepatic lipids and lipid peroxidation in rats fed on a high-cholesterol diet
39. Enhanced oral bioavailability of paclitaxel by d-α-tocopheryl polyethylene glycol 400 succinate in mice
40. Anti-angiogenic action of 5,5-diphenyl-2-thiohydantoin-N10 (DPTH-N10)
41. Intravenous paclitaxel against metastasis of human gastric tumors of diffuse type
42. Human Breast Tumor Cells Express Multimodal Imaging Reporter Genes
43. Effects of paclitaxel and doxorubicin in histocultures of hepatocelular carcinomas
44. Development and validation of a liquid chromatography–tandem mass spectrometry for the determination of BPR0L075, a novel antimicrotuble agent, in rat plasma: Application to a pharmacokinetic study
45. A Natural Compound (Ginsenoside Re) Isolated from Panax ginseng as a Novel Angiogenic Agent for Tissue Regeneration
46. Paclitaxel-loaded poly( γ-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer
47. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes
48. Engineering Nano‐ and Microparticles as Oral Delivery Vehicles to Promote Intestinal Lymphatic Drug Transport.
49. BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities
50. Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.